Companies · Biotech / Pharma

Nueva Bio LLC

PALO ALTO · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Nueva Bio LLC — recommendation, valuation, rhythm, risks.
$17.5M
Total raised · real
1
Rounds
Latest step-up
Top 28%
Sector rank · raised
Series B
Latest stage · inferred · Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Nueva Bio LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.21× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
  • Within the normal band (121% of peer median) for its niche.
Dormant
  • Last raise 4.3 yr ago; this sector typically re-raises about every 15 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Nueva Bio LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
4.3 yr record
Peak capital year was 2022 with $17.5M across 1 filings.
Market position
ahead of 73% of Biotech / Pharma peers
Capital scale is ahead of 73% of Biotech / Pharma peers; modeled value is above 86% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $17.5M across 1 filings.
  • Largest single filing was $17.5M on 2022-03-15.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Nueva Bio LLC is one of 227 Biotech / Pharma companies tracked from PALO ALTO. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2021
Year incorporated
2022-03-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries B · 2022-03-15 Raised $18M (real) Modeled valuation $319M (est)$18M$319MSeries B2022

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$17.5M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$318.8M
Base estimate est.
$35.9M
Conservative case
$885.6M
Upside case
$97.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
56%
Survival probability
37% low · 68% high
1.51×/yr
Annual markup
1.83×/yr upside case
4.3 yr
Elapsed time used
4.3 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
4.3 yr
On record since
2022
First round
1
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$17.5M
Sector median$5.6M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$17.5M
Sector median$18.7M
Modeled value — vs sector median (estimate, all stages) 10× above median
This company$318.8M
Sector median$30.5M

Raised more than 73% of sector peers (real $). Modeled value above 86% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 15.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Carbon Biosciences, Inc. · Series B Raised $38.0M · modeled $743.9M (est)Slingshot Biosciences, Inc. · Series B Raised $49.1M · modeled $334.7M (est)Telesis Bio Inc. · Series B Raised $28.0M · modeled $307.9M (est)Turn Biotechnologies, Inc. · Series B Raised $29.1M · modeled $293.3M (est)Surf Bio, Inc. · Series B Raised $16.0M · modeled $287.6M (est)Prellis Biologics, Inc · Series B Raised $47.3M · modeled $276.9M (est)Appello Pharmaceuticals, Inc. · Series B Raised $29.0M · modeled $263.4M (est)Protillion Biosciences, lnc. · Series B Raised $19.0M · modeled $256.3M (est)Orange Grove Bio LLC · Series B Raised $16.6M · modeled $255.6M (est)Ganymede Bio, Inc. · Series B Raised $15.2M · modeled $238.6M (est)Q Bio, Inc. · Series B Raised $27.1M · modeled $213.6M (est)Nueva Bio LLC (this company) Raised $17.5M · modeled $318.8M (est)Nueva Bio LLC
CompanyStageRaised · realValue · estvs peer med.
Carbon Biosciences, Inc.Series B$38.0M$743.9M2.82×
Slingshot Biosciences, Inc.Series B$49.1M$334.7M1.27×
Nueva Bio LLC this companySeries B$17.5M$318.8M1.21×
Telesis Bio Inc.Series B$28.0M$307.9M1.17×
Turn Biotechnologies, Inc.Series B$29.1M$293.3M1.11×
Surf Bio, Inc.Series B$16.0M$287.6M1.09×
Prellis Biologics, IncSeries B$47.3M$276.9M1.05×
Appello Pharmaceuticals, Inc.Series B$29.0M$263.4M1.00×
Protillion Biosciences, lnc.Series B$19.0M$256.3M0.97×
Orange Grove Bio LLCSeries B$16.6M$255.6M0.97×
Ganymede Bio, Inc.Series B$15.2M$238.6M0.91×
Q Bio, Inc.Series B$27.1M$213.6M0.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$17.5M2022-03-15$97.3M$318.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$17.5M2022-03-15
    • First recorded raise — entered as Series B.
    • 6 investors on this round.
Intelligence
Modeled next raise
$28.0M
Modeled next size est.range $18.2M$44.8M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gangadhara Ganapati2 other2022-03
Registry & provenance

Nueva Bio LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1918813
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Curve Biosciences, Inc.Biotech / PharmaSeries B$17.7M$133.9Msame sector · same stage
WPD Pharmaceuticals Inc.Biotech / PharmaSeries B$17.7M$32.7Msame sector · same stage
LifeVault Bio, Inc.Biotech / PharmaSeries B$17.9M$594.6Msame sector · same stage
Orange Grove Bio LLCBiotech / PharmaSeries B$16.6M$255.6Msame sector · same stage
Protillion Biosciences, lnc.Biotech / PharmaSeries B$19.0M$256.3Msame sector · same stage
Surf Bio, Inc.Biotech / PharmaSeries B$16.0M$287.6Msame sector · same stage
Paragon Biosciences CIRC Holdings, LLCBiotech / PharmaSeries B$15.8M$511.8Msame sector · same stage
Pillar Biosciences Inc.Biotech / PharmaSeries B$20.0M$511.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
NJ BIO, Inc.Biotech / PharmaSeries A$54.9M84%
New Frontier Bio, Inc.Biotech / PharmaSeries A$1.7M84%
Outer Biosciences, LLCBiotech / PharmaSeed$66.0M83%
PharmaCann Inc.Biotech / PharmaSeries D+$413.1M83%
Nalu Bio, Inc.Biotech / PharmaSeries A$48.4M83%
Novome Biotechnologies, Inc.Biotech / PharmaPre-Seed$27.4M82%
Q Bio, Inc.Biotech / PharmaSeries B$213.6M82%
Puna Bio CorpBiotech / PharmaSeries B$108.5M82%
Frequently asked
How much funding has Nueva Bio LLC raised?
Nueva Bio LLC has raised approximately $17.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Nueva Bio LLC's estimated valuation?
Provath's modeled valuation for Nueva Bio LLC is approximately $318.8M (modeled range $35.9M–$885.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nueva Bio LLC at?
Nueva Bio LLC's latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Mar 15.
What does Nueva Bio LLC do and where is it based?
Nueva Bio LLC operates in the Biotech / Pharma sector, based in PALO ALTO.
Explore related

See where Nueva Bio LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nueva Bio LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.